A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the safety of MabThera plus methotrexate in patients with
rheumatoid arthritis who have had a lack of response to 1-5 DMARDs or biological agents.
Patients will receive MabThera (1g i.v.) on days 1 and 15, concomitantly with methotrexate
>=15mg p.o./week. The anticipated time on study treatment is 3-12 months, and the target
sample size is 100-500 individuals.